February 11, 2025

LIGHTSITE III Data Answers and Raises Questions about Photobiomodulation Therapy for AMD

The trial met the primary endpoint with a statistically significant +5.4 letter gain in BCVA and a favorable safety profile, but experts raised additional questions after the FDA cleared marketing for a PBM device.

Conexiant

February 06, 2025

AMD and Glaucoma Management Made Easier: The Value of Community Optometrists vs Hospital Care

“Patients perceived primary care-based clinics to be more accessible geographically and being able to negotiate appointment times was also important. Others have found that this can lead to greater engagement with eye care services.”

Conexiant

January 22, 2025

High, Low HDLs Tied to AMD Risk

The lack of association between LDLs and triglycerides and AMD risk “suggests that plasma HDL specifically may play a role in progression to early and intermediate AMD.”

Conexiant

January 22, 2025

Medicare Advantage and Traditional Medicare Enrollees’ Use of Benefits

Socioeconomically disadvantaged patients tend to use less care relative to their medical needs—regardless of their coverage—than others.

Conexiant

January 16, 2025

LA County Fires Prompt Business Recovery Centers to Open

"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."

Optometric Management

August 01, 2023

E-insights Into the Latest in Patient Care and Practice Management

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Optometric Management

September 18, 2024

Assessing the Impact of iRORA Lesions on Retina Sensitivity and Function

A new case study explores the impact of incomplete retinal pigment epithelium and outer retinal atrophy lesions on retinal sensitivity in intermediate age-related macular degeneration, shedding light on potential surrogate markers for retinal dysfunction. (Source: BMJ Open Ophthalmology)

Conexiant

September 30, 2024

Can L-DOPA Protect Against nAMD?

Patients consistently treated with L-DOPA also had lower progression rates from intermediate AMD to nAMD compared to non-treated groups.

Conexiant

October 01, 2023

Preventing Conversion to Advanced AMD

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Optometric Management